Novartis AG (NVS) Stock Competitors & Peer Comparison
See (NVS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVS | $148.96 | +1.73% | 284.5B | 21.36 | $6.98 | +3.17% |
| LLY | $1,152.50 | +0.29% | 1.1T | 40.61 | $28.17 | +0.56% |
| JNJ | $239.09 | +2.99% | 570.7B | 27.44 | $8.64 | +2.21% |
| ABBV | $226.34 | +1.47% | 398.2B | 109.93 | $2.05 | +2.98% |
| MRK | $118.13 | -1.16% | 295.3B | 33.68 | $3.55 | +2.76% |
| AZN | $180.14 | -0.78% | 284.4B | 27.61 | $6.64 | +1.74% |
| AMGN | $346.39 | +0.19% | 186B | 23.98 | $14.37 | +2.85% |
| GILD | $122.84 | -4.11% | 155.8B | 14.99 | $8.37 | +2.54% |
| PFE | $25.71 | +0.33% | 146.3B | 19.60 | $1.31 | +6.68% |
| BMY | $56.15 | +1.04% | 115.3B | 15.82 | $3.57 | +4.43% |
Stock Comparison
NVS vs LLY Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, LLY has a market cap of 1.1T. Regarding current trading prices, NVS is priced at $148.96, while LLY trades at $1,152.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas LLY's P/E ratio is 40.61. In terms of profitability, NVS's ROE is +0.32%, compared to LLY's ROE of +1.01%. Regarding short-term risk, NVS is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check LLY's competition here
NVS vs JNJ Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, JNJ has a market cap of 570.7B. Regarding current trading prices, NVS is priced at $148.96, while JNJ trades at $239.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas JNJ's P/E ratio is 27.44. In terms of profitability, NVS's ROE is +0.32%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, NVS is less volatile compared to JNJ. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check JNJ's competition here
NVS vs ABBV Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, ABBV has a market cap of 398.2B. Regarding current trading prices, NVS is priced at $148.96, while ABBV trades at $226.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas ABBV's P/E ratio is 109.93. In terms of profitability, NVS's ROE is +0.32%, compared to ABBV's ROE of +0.68%. Regarding short-term risk, NVS is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check ABBV's competition here
NVS vs MRK Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, MRK has a market cap of 295.3B. Regarding current trading prices, NVS is priced at $148.96, while MRK trades at $118.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas MRK's P/E ratio is 33.68. In terms of profitability, NVS's ROE is +0.32%, compared to MRK's ROE of +0.18%. Regarding short-term risk, NVS is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check MRK's competition here
NVS vs AZN Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, AZN has a market cap of 284.4B. Regarding current trading prices, NVS is priced at $148.96, while AZN trades at $180.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas AZN's P/E ratio is 27.61. In terms of profitability, NVS's ROE is +0.32%, compared to AZN's ROE of +0.22%. Regarding short-term risk, NVS is less volatile compared to AZN. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check AZN's competition here
NVS vs AMGN Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, AMGN has a market cap of 186B. Regarding current trading prices, NVS is priced at $148.96, while AMGN trades at $346.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas AMGN's P/E ratio is 23.98. In terms of profitability, NVS's ROE is +0.32%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, NVS is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check AMGN's competition here
NVS vs GILD Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, GILD has a market cap of 155.8B. Regarding current trading prices, NVS is priced at $148.96, while GILD trades at $122.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas GILD's P/E ratio is 14.99. In terms of profitability, NVS's ROE is +0.32%, compared to GILD's ROE of +0.42%. Regarding short-term risk, NVS is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check GILD's competition here
NVS vs PFE Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, PFE has a market cap of 146.3B. Regarding current trading prices, NVS is priced at $148.96, while PFE trades at $25.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas PFE's P/E ratio is 19.60. In terms of profitability, NVS's ROE is +0.32%, compared to PFE's ROE of +0.08%. Regarding short-term risk, NVS is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check PFE's competition here
NVS vs BMY Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, BMY has a market cap of 115.3B. Regarding current trading prices, NVS is priced at $148.96, while BMY trades at $56.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas BMY's P/E ratio is 15.82. In terms of profitability, NVS's ROE is +0.32%, compared to BMY's ROE of +0.39%. Regarding short-term risk, NVS is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check BMY's competition here
NVS vs SNY Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, SNY has a market cap of 107.7B. Regarding current trading prices, NVS is priced at $148.96, while SNY trades at $43.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas SNY's P/E ratio is 19.45. In terms of profitability, NVS's ROE is +0.32%, compared to SNY's ROE of +0.11%. Regarding short-term risk, NVS is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check SNY's competition here
NVS vs GSK Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, GSK has a market cap of 103B. Regarding current trading prices, NVS is priced at $148.96, while GSK trades at $51.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas GSK's P/E ratio is 13.52. In terms of profitability, NVS's ROE is +0.32%, compared to GSK's ROE of +0.28%. Regarding short-term risk, NVS is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check GSK's competition here
NVS vs ZTS Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, ZTS has a market cap of 34.4B. Regarding current trading prices, NVS is priced at $148.96, while ZTS trades at $82.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas ZTS's P/E ratio is 13.46. In terms of profitability, NVS's ROE is +0.32%, compared to ZTS's ROE of +0.62%. Regarding short-term risk, NVS is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check ZTS's competition here
NVS vs BIIB Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, BIIB has a market cap of 29.4B. Regarding current trading prices, NVS is priced at $148.96, while BIIB trades at $198.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas BIIB's P/E ratio is 21.41. In terms of profitability, NVS's ROE is +0.32%, compared to BIIB's ROE of +0.08%. Regarding short-term risk, NVS is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check BIIB's competition here
NVS vs HZNP Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVS is priced at $148.96, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVS's ROE is +0.32%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVS is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for NVS.Check HZNP's competition here
NVS vs GRFS Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, GRFS has a market cap of 6.2B. Regarding current trading prices, NVS is priced at $148.96, while GRFS trades at $7.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas GRFS's P/E ratio is 10.34. In terms of profitability, NVS's ROE is +0.32%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, NVS is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check GRFS's competition here
NVS vs OGN Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, OGN has a market cap of 3.5B. Regarding current trading prices, NVS is priced at $148.96, while OGN trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas OGN's P/E ratio is 14.41. In terms of profitability, NVS's ROE is +0.32%, compared to OGN's ROE of +0.30%. Regarding short-term risk, NVS is more volatile compared to OGN. This indicates potentially higher risk in terms of short-term price fluctuations for NVS.Check OGN's competition here
NVS vs CELG-RI Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, CELG-RI has a market cap of 219.5M. Regarding current trading prices, NVS is priced at $148.96, while CELG-RI trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.32%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, NVS is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check CELG-RI's competition here
NVS vs CTOR Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, CTOR has a market cap of 64.6M. Regarding current trading prices, NVS is priced at $148.96, while CTOR trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas CTOR's P/E ratio is -1.45. In terms of profitability, NVS's ROE is +0.32%, compared to CTOR's ROE of -0.99%. Regarding short-term risk, NVS is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check CTOR's competition here
NVS vs SCLX Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, SCLX has a market cap of 59.8M. Regarding current trading prices, NVS is priced at $148.96, while SCLX trades at $7.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas SCLX's P/E ratio is -0.17. In terms of profitability, NVS's ROE is +0.32%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, NVS is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check SCLX's competition here
NVS vs MIRA Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, MIRA has a market cap of 41M. Regarding current trading prices, NVS is priced at $148.96, while MIRA trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas MIRA's P/E ratio is -0.77. In terms of profitability, NVS's ROE is +0.32%, compared to MIRA's ROE of -1.41%. Regarding short-term risk, NVS is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check MIRA's competition here
NVS vs SRXH Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, SRXH has a market cap of 4.1M. Regarding current trading prices, NVS is priced at $148.96, while SRXH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas SRXH's P/E ratio is -0.71. In terms of profitability, NVS's ROE is +0.32%, compared to SRXH's ROE of +8.75%. Regarding short-term risk, NVS is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check SRXH's competition here
NVS vs SCLXW Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, SCLXW has a market cap of 1.4M. Regarding current trading prices, NVS is priced at $148.96, while SCLXW trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.32%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, NVS is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check SCLXW's competition here
NVS vs CRXT Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVS is priced at $148.96, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVS's ROE is +0.32%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVS is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check CRXT's competition here
NVS vs BDSIW Comparison June 2026
NVS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVS stands at 284.5B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, NVS is priced at $148.96, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVS currently has a P/E ratio of 21.36, whereas BDSIW's P/E ratio is N/A. In terms of profitability, NVS's ROE is +0.32%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, NVS is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for NVS.Check BDSIW's competition here